— and it aims to supply vaccines to 20 percent of the population in each of its 180 participating nations.
The investment bank Morgan Stanley projects their drug could make $15 billion revenue this year and the next. Pfizer said it was unable to comment on ongoing negotiations. A spokesman for Gavi, the Vaccine Alliance, which is co-leading COVAX, declined to offer specifics but said with any purchase it would"look for the lowest price available, given the volume it represents and populations it serves."
Even if this labyrinthine logistics puzzle is solved, public health workers must then convince patients to actually take the shots.found more than a quarter said they'd shun any vaccine approved by regulators. In Russia, Poland, Hungary and France, the proportion of naysayers rises to more than 40 percent.
More tax dollars included.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.